Dendrimers for genomic analysis methods and compositions
US-2024301515-A1 · Sep 12, 2024 · US
US10364293B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10364293-B2 |
| Application number | US-201515310585-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 21, 2015 |
| Priority date | May 23, 2014 |
| Publication date | Jul 30, 2019 |
| Grant date | Jul 30, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor. The polypeptide is useful for the development of agents for the prevention or diseases associated with overexpression of epidermal growth factor receptor.
Opening claim text (preview).
The invention claimed is: 1. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8. 2. The polypeptide of claim 1 , wherein the polypeptide has the ability to bind to the extracellular domain of epidermal growth factor receptor to inhibit the activity of the epidermal growth factor domain. 3. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8, wherein the polypeptide comprises a fusion of the N-terminus of internalin B protein, a modified repeat module of variable lymphocyte receptor (VLR) protein, and the C-terminus of the VLR protein. 4. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8, wherein the modified repeat module of the VLR protein comprises the following repeat module pattern: LxxLxxLxLxxN (SEQ ID NO: 10) wherein L is alanine, glycine, phenylalanine, tyrosine, leucine, isoleucine, valine, or tryptophan, N is asparagine, glutamine, seine, cysteine, or threonine, and x is any one of all 20 amino acids. 5. A polynucleotide that encodes the polypeptide of claim 1 . 6. A recombinant vector comprising the polynucleotide of claim 5 . 7. A recombinant microorganism having introduced therein the polynucleotide of claim 5 . 8. A recombinant microorganism having introduced therein the polynucleotide of claim 6 . 9. A method for producing a polypeptide binding specifically to epidermal growth factor receptor protein, comprising the steps of: (i) culturing the recombinant microorganism of claim 7 to produce a polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises an amino acid sequence of any one of SEQ ID NOS: 6 to 8; and (ii) recovering the polypeptide of claim 1 from the cultured recombinant microorganism or the culture. 10. A composition for preventing or treating cancer, which comprises the polypeptide of claim 1 . 11. The composition of claim 10 , wherein the prevention or treatment of cancer is achieved by the binding of the polypeptide to epidermal growth factor receptor.
from vertebrates · CPC title
for growth factors; for growth regulators · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
DNA sequences coding for fusion proteins · CPC title
Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.